Floatz logo

LECANEMAB

Mild Cognitive Impairment

Ali Rezaimonoclonal_antibodyEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

149 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

LECANEMAB is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
71 / 100
View asset →
familial Alzheimer diseaseDormant
BB
Indicative ·
66 / 100
View asset →
Alzheimer diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →